We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Biomea Fusion Inc (BMEA) USD0.0001

Sell:$12.00 Buy:$12.03 Change: $0.08 (0.67%)
Market closed |  Prices as at close on 27 June 2022 | Switch to live prices |
Change: $0.08 (0.67%)
Market closed |  Prices as at close on 27 June 2022 | Switch to live prices |
Change: $0.08 (0.67%)
Market closed |  Prices as at close on 27 June 2022 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Biomea Fusion, Inc. is a preclinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of irreversible small molecule drugs to treat patients with genetically defined cancers. The Company has built FUSION System discovery platform to advance a pipeline of irreversible small molecule product candidates. The Company's lead product candidate, BMF-219, is designed to be an orally bioavailable, potent and selective irreversible inhibitor of menin, an important transcriptional regulator known to play a direct role in oncogenic signaling in multiple cancers. The Company is developing BMF-219 for the treatment of liquid and solid tumors that are dependent on menin, including leukemias containing the mixed lineage leukemia (MLL) fusion protein. The Company is also advancing other preclinical irreversible programs for the treatment of select cancers.

Contact details

900 Middlefield Road, 4Th Floor
United States
+1 (650) 9809099

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$348.57 million
Shares in issue:
29.62 million
United States
US dollar

Key personnel

  • Thomas Butler
    Chairman of the Board, Chief Executive Officer, Co-Founder
  • Rainer Erdtmann
    President, Co-Founder, Chief Operating Officer, Director
  • Franco Valle
    Chief Financial Officer, Principal Accounting Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.